Casimir A. Kulikowski is Board of Governors Professor of Computer Science at Rutgers University. He earned a Ph.D. in electrical engineering from the University of Hawaii. His research interests include bioinformatics, medical informatics, and artificial intelligence. In bioinformatics, he is working on pattern recognition and clustering methods for genomics and proteomics, and consensus classification methods for comparative genomic analysis and annotation. Dr. Kulikowski is also working on models for clinical guidelines, on methods of medical decision support, biomedical imaging, and predictive data mining. He has served on the NRC Committee to Address “Information Infrastructure for Health and Health Care” and the Committee to Review the Social Security Administration’s System Modernization and Strategic Plan. Dr. Kulikowski was elected to the Institute of Medicine in 1988.
George Orphanides is head of investigative toxicology and Stage 1 toxicology at Syngenta in the United Kingdom. Previously he has held roles as head of receptor biology and genomics at Syngenta and group leader for toxicogenomics at AstraZeneca. His research interests in the area of toxicogenomics include gene expression profiling, proteomics, mechanisms of gene regulation, transcription factors, nuclear receptors, chromatin dynamics, estrogenic compounds, and bioinformatics. He currently serves on several committees, including vice-chair of the ILSI-HESI Committee on the Application of Genomics in Risk Assessment; the ECVAM (European Centre for the Validation of Alternative Test Methods) Committee on the Validation of Toxicogenomics-Based Alternative Methods; and the IPCS (International Programme on Chemical Safety) Committee on Toxicogenomics and the Risk Assessment of Chemicals in the Protection of Human Health, where he is co-chair of the Subcommittee on Human Susceptibility and Exposure. He currently serves on the editorial board of the journal Biomarkers. Dr. Orphanides received his Ph.D. in biochemistry from the University of Leicester, United Kingdom.
Lawrence M. Sung holds the appointment of law school professor and director of the Intellectual Property Law Program at the University of Maryland Law School. He is also a partner with the Washington, DC intellectual property law firm of Schwartz, Sung & Webster. His area of expertise is in patent and technology transfer issues concerning the biotechnology, pharmaceutical and medical device industries. He has previously taught at the law schools of George Washington University, American University, Lewis & Clark College, and Seattle University.